Pfizer expects sales to fall as much as 33 percent in 2023

Pfizer announced its balance sheet for the fourth quarter of 2022. In the statement, it was noted that the company’s revenue in the last quarter of last year increased 2 percent compared to the same period of 2021 to $24.3 thousand. millions.

In the statement, it was noted that Pfizer’s revenue increased 23 percent compared to the previous year in 2022 and reached $100.3 billion, which is the highest revenue the company has ever achieved.

In the statement, it was indicated that the company’s revenue in 2023 is expected to decrease by 29 to 33 percent compared to last year, noting that the revenue estimate for this year is between 67,000 and 71,000 millions of dollars.

In the statement, it was noted that revenue from the Covid-19 vaccine developed with BioNTech is expected to decline by 64 percent to $13.5 billion, and revenue from the antiviral drugs Paxlovid to $8 billion with a decrease of the 58 percent. (AA)